NCT07514234Completed
Optimal Allogeneic PRP Concentration for Oocyte In Vitro Maturation in Women With PCOS
Optimal Allogenic Platelet-rich Plasma Concentration to Improves in Vitro Maturation of Germinal Vesicle Oocytes From Women With PCOS: A Prospective Cohort Study
Source: ClinicalTrials.gov · Last updated 7 Apr 2026
Brief summary (registry, in English)
In vitro maturation is a long-studied technique used to obtain mature oocytes outside the human body. However, this method can increase the risk of ovarian hyperstimulation syndrome (OHSS), particularly in patients with polycystic ovarian syndrome (PCOS). Culture media supplemented with platelet-rich plasma (PRP) has previously shown promise for improving oocyte maturation. This study examined the potential utility of allogeneic PRP supplementation to increase the maturation of germinal vesicle (GV)-stage oocytes collected from PCOS patients who underwent controlled ovarian stimulation. Supplementation with 5% PRP was found to support oocyte maturation under controlled ovarian stimulation. Further investigations are required to refine the use of PRP without controlled ovarian stimulation in clinical IVM protocols that may be beneficial for PCOS patients.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 15 (actual)
- First submitted
- 23 Mar 2026
- Start date
- 5 Jan 2023
- Primary completion date
- 11 Sept 2023
- Lead sponsor
- Gadjah Mada University
- NCT number
- NCT07514234
What you commit to
- Study type: Interventional
- Participants enrolled: 15
- From 5 Jan 2023 to the primary completion date, 11 Sept 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \- Oocytes obtained from patients with comorbid conditions, including cancer, congenital adrenal hyperplasia, Cushing's syndrome, premature ovarian failure (POF) or premature ovarian insufficiency, liver disorders, kidney disease, cardiovascular disease, diabetes mellitus (type 1 or type 2), and patients receiving steroid therapy
Who the study is looking for
- Immature oocytes at the germinal vesicle (GV) stage
- Oocytes obtained from patients fulfilling clinical and laboratory diagnostic criteria for PCOS, defined by the presence of at least two of the following three characteristics: clinical hyperandrogenism and/or biochemical hyperandrogenemia, ovulatory dysfunction (oligomenorrhea or anovulation), and polycystic ovarian morphology (≥12 follicles measuring 2-9 mm in each ovary on ultrasonography)
- Oocytes collected from patients undergoing ovarian stimulation using the same ovarian stimulation protocol.
- Oocytes obtained from patients with primary infertility
- Oocytes obtained from treatment-naive patients with PCOS.
Age in the registry: 30 years to 41 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dr. Sardjito General Hospital Coordinator of this site? Confirm its status | Yogyakarta | Indonesia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.